This scholarly commentary provides a comprehensive critical evaluation of the paper by Burger et al., “Synthetic α-synuclein fibrils replicate in mice causing MSA-like pathology,” published in Nature (2025). The original study claims that recombinant α-synuclein fibrils, when injected into the mouse brain, undergo in vivo replication and induce pathology analogous to that observed in multiple system atrophy (MSA). Because these conclusions have profound implications for neurodegeneration research, mechanistic modeling, and therapeutic development, rigorous scrutiny is essential. This commentary examines the conceptual framework, methodology, data interpretation, and translational relevance of the study across multiple analytic dimensions. Through a structured, figure-by-figure critique—including all main Figures, Extended Data Figures, and Supplementary Figures—the commentary identifies substantial methodological shortcomings that undermine the central claim of strain replication. Key deficiencies include insufficient structural characterization of the synthetic fibrils, lack of evidence demonstrating conformational fidelity between injected and recovered aggregates, inadequate controls for inflammation-driven pathology, and limited validation of in vivo propagation mechanisms. Histopathological findings are sparse and inconsistent, failing to reproduce the morphological, biochemical, and ultrastructural hallmarks of authentic glial cytoplasmic inclusions seen in human MSA. Behavioral results are modest, variable, and underpowered, offering little support for progressive neurodegeneration. Transcriptomic analyses reveal broad stress-response signatures rather than disease-specific patterns characteristic of MSA. The commentary emphasizes that several alternative explanations—including injection-induced inflammation, contamination, nonspecific proteostasis disruption, and species-specific glial vulnerabilities—are more parsimonious than the replication hypothesis. Furthermore, profound biological differences between mouse and human oligodendrocytes limit the translational relevance of the model. The analysis argues that misinterpretation of such models can distort mechanistic understanding, misdirect therapeutic development, and contribute to broader reproducibility challenges in proteinopathy research. Overall, this commentary reframes the study’s findings by delineating what the evidence does and does not support. It offers constructive recommendations for improving experimental rigor, structural validation, data transparency, and model development. By clarifying conceptual boundaries and methodological requirements, the work aims to guide the field toward more reliable and physiologically grounded approaches for investigating α-synuclein biology and the pathogenesis of MSA.